Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants

Journal of Pharmacology and Experimental Therapeutics

Volumn 288, Issue 3, 1999, Pages 1317-1326

  Sawada, Geri A ^a   Barsuhn, Craig L ^a   Lutzke, Barry S ^a   Houghton, Michael E ^a,b   Padbury, Guy E ^a   Ho, Norman F H ^a,c   Raub, Thomas J ^a  

^a PFIZER INC   (United States)

^b 3M COMPANY   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,4 DIAMINO PYRROLO[2,3 D]PYRIMIDINE DERIVATIVE; ANTIOXIDANT; PNU 78517E; PNU 87663; PNU 89843; UNCLASSIFIED DRUG;

ANIMAL CELL; ANTIOXIDANT ACTIVITY; ARTICLE; CELL SEPARATION; DOSE TIME EFFECT RELATION; DRUG DIFFUSION; DRUG PENETRATION; LIPID PEROXIDATION; LIPOPHILICITY; MEAN RESIDENCE TIME; MOLECULAR INTERACTION; NEUROPROTECTION; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL;

ANIMALS; ANTIOXIDANTS; CELL LINE; CELL MEMBRANE PERMEABILITY; DIFFUSION; DOGS; HYDROGEN-ION CONCENTRATION; LIPID PEROXIDATION; OXIDATIVE STRESS; PYRIMIDINES; PYRROLES; PYRROLIDINES; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 0033055351     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Andrus PK, Fleck TJ, Oosteveen JA and Hall ED (1997) Neuroprotective effects of the novel brain-penetrating pyrrolopyrimidine antioxidants U-101033E and U-104067F against post-ischemic degeneration of nigrostriatal neurons. J Neurosci Res 47:650-654.
2. Artursson P and Karlsson J (1991) Correlation between oral drug absorption in humans and apparent drug permeability coefficients in human intestinal epithelial Caco-2 cells. Biochem Biophys Res Commun 175:880-885.
3. Bernards CM and Hill HF (1992) Physical and chemical properties of drug molecules governing their diffusion through the spinal meninges. Anesthesiology 77:750-756.
4. Bundy GL, Ayer DE, Banitt LS, Belonga KL, Mizsak SA, Palmer JR, Tustin JM, Chin JE, Hall ED, Linesman KL, Richards IM, Scherch IM, Sun FF, Yonkers PA, Larson PG, Lin JM, Padbury GE, Aaron CS and Mayo JK (1995) Synthesis of novel 2,4-diaminopyrrolo-[2,3-d]pyrimidines with antioxidant, neuroprotective, and antiasthma activity. J Med Chem 38:4161-4163.
5. Burton PS, Conradi RA, Hilgers AR, Ho NFH and Maggiora LL (1992) The relationship between peptide structure and transport across epithelial cell monolayers. J Control Rel 19:87-98.
6. Burton PS, Goodwin JT, Conradi RA, Ho NFH and Hilgers AR (1997) In vitro permeability of peptidomimetic drugs: The role of polarized efflux pathways as additional barriers to absorption. Adv Drug Delivery Rev 23:143-156.
7. Epps DE and McCall JM (1997) Physical and chemical mechanisms of the antioxidant action of tirilazad mesylate, in Handbook of Synthetic Antioxidants (Packer L and Cadenas E eds) pp 95-137, Marcel Dekker, New York.
8. Folch J, Lees M and Sloane-Stanley GH (1957) A simple method for the isolation and purification of total lipids from animal tissues. J Biol Chem 226:497-509.
9. Grieg NH (1989) Drug delivery to the brain by blood-brain barrier circumvention and drug modification, in Implications of the Blood-Brain Barrier and Its Manipulation vol 1, pp 311-368, Plenum, New York.
10. Hall ED, McCall JM and Means ED (1994) Therapeutic potential of the lazaroids (21-aminosteroids) in acute central nervous system trauma, ischemia and sub-arachnoid hemorrhage. Adv Pharmacol 28:221-268.
11. Hall ED, Andrus PK, Smith SL, Fleck TJ, Scherch HM, Lutzke BS, Sawada GA, Althaus JS, Vonvoigtlander PF, Padbury GE, Larson PG, Palmer JR and Bundy GL (1997) Pyrrolopyrimidines: Novel brain-penetrating pyrrolopyrimidine antioxidants with neuroprotective activity in brain injury and ischemia models. J Pharmacol Exp Ther 281:895-904.
12. Hansch C and Clayton JM (1973) Lipophilic character and biological activity of drugs. II: The parabolic case. J Pharm Sci 62:1-21.
13. Hansch C and Leo A (1995) Exploring QSAR: Fundamentals and Applications in Chemistry and Biology pp 161-168. American Chemical Society, Washington, DC.
14. Laizure SC, Franklin LK and Kaiser DG (1993) Disposition of tirilazad (U74006F), a 21-aminosteroid, in the plasma, heart, brain, and liver of the rat. Drug Metab Dispos 21:951-954.
15. Lees GJ (1993) Contributory mechanisms in the causation of neurodegenerative disorders. Neuroscience 54:287-322.
16. Nau R, Sorgel F and Prange HW (1994) Lipophilicity at pH 7.4 and molecular size govern the entry of the free serum fraction of drugs into the cerebrospinal fluid in humans with inflamed meninges. J Neurol Sci 122:61-65.
17. Nook T, Doelker E and Buri P (1988) Intestinal absorption kinetics of various model drugs in relation to partition coefficients. Int J Pharm 43:119-129.
18. Perrin DD, Dempsey B and Serjeant EP (1981) pKa Prediction for Organic Acids and Bases. Chapman & Hall, New York.
19. Raub TJ, Barsuhn CB, Williams LR, Decker DE, Sawada GA and Ho NFH (1993) Application of a biophysical-kinetic model to understand the roles of protein binding and membrane partitioning on passive diffusion of highly lipophilic molecules across cellular barriers. J Drug Targeting 1:269-286.
20. Ridout G, Houk J and Guy RH (1992) An evaluation of structure-penetration relationships in percutaneous absorption. Il Farmaco 47:869-892.
21. Saji H, Tokui T, Nakatsuka I, Saiga A, Magata Y, Shiba K, Yoshitake A and Yokohama A (1992) Evaluation of N-alkyl derivatives of radioiodinated spiperone as radioligands for in vivo dopamine D2 receptor studies: Effects of lipophilicity and receptor affinity on the in vivo biodistribution. Chem Pharm Bull 40:165-169.
22. Sawada GA, Ho NFH, Williams LR, Barsuhn CL and Raub TJ (1994) Transcellular permeability of chlorpromazine demonstrating the roles of protein binding and membrane partitioning. Pharm Res 11:665-673.
23. Sawada GA, Williams LR and Raub TJ (1999) Novel, highly lipophilic antioxidants readily diffuse across the blood-brain barrier and access intracellular sites, J Pharmacol Exp Ther 288:1327-1333.
24. van de Waterbeemd H and Kansy M (1992) Hydrogen-bonding capacity and brain penetration. Chimia 46:299-303.
25. Wils P, Warnery A, Phung-Ba V, Legrain S and Scherman D (1994a) High lipophilicity decreases drug transport across intestinal epithelial cells. J Pharmacol Exp Ther 269:654-658.
26. Wils P, Warnery A, Phung-Ba V, Legrain S and Scherman D (1994b) Differentiated intestinal epithelial cell lines as in vitro models for predicting the intestinal absorption of drugs. Cell Biol Toxicol 10:393-397.
27. Wright EM and Diamond JM (1969) Patterns of non-electrolyte permeability. Proc R Soc B 172:227-271.
28. Yalkowski SH and Morozowich W (1980) A physical-chemical basis for the design of orally active prodrugs. Drug Design 9:122-185.